Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma

Roland Buhl, Ilona Vinkler, P. Magyar, Zsuzsa Györi, Cezary Rybacki, Michelle Vivienne Middle, Armella Escher, Renate Engelstätter

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Inhaled corticosteroids are the mainstay of therapy in asthma, but local and systemic side effects and adherence remain a concern. Ciclesonide is an inhaled corticosteroid with on-site lung activation that provides potent anti-inflammatory activity and has been shown to have a good safety profile, even at high doses. Objective: The aim of this study was to compare the efficacy and safety of once-daily ciclesonide versus twice-daily fluticasone propionate at comparable daily doses in patients with asthma. Methods: In this multicenter, randomized, double-blind, double-dummy, parallel group study, 529 patients were randomized to ciclesonide 160 μg once daily or fluticasone propionate 88 μg twice daily for 12 weeks. The primary endpoint was change in lung function. Results: Both ciclesonide and fluticasone propionate significantly improved forced expiratory volume in 1 s, forced vital capacity, and morning peak expiratory flow compared with baseline (p <0.0001 for all variables). Both medications reduced asthma symptoms and rescue medication use within the first 24 h. At the tested dose, both medications were equally safe and well tolerated. Conclusion: Ciclesonide 160 μg once daily was as effective as fluticasone propionate 88 μg twice daily in improving lung function and asthma symptoms, and in reducing rescue medication use in patients with asthma.

Original languageEnglish
Pages (from-to)404-412
Number of pages9
JournalPulmonary Pharmacology and Therapeutics
Volume19
Issue number6
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Asthma
Lung
Adrenal Cortex Hormones
Safety
Vital Capacity
Forced Expiratory Volume
Anti-Inflammatory Agents
Chemical activation
ciclesonide
Fluticasone
Therapeutics

Keywords

  • Asthma
  • Ciclesonide
  • Fluticasone propionate
  • Inhaled corticosteroid
  • Oral candidiasis
  • Pulmonary function

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. / Buhl, Roland; Vinkler, Ilona; Magyar, P.; Györi, Zsuzsa; Rybacki, Cezary; Middle, Michelle Vivienne; Escher, Armella; Engelstätter, Renate.

In: Pulmonary Pharmacology and Therapeutics, Vol. 19, No. 6, 12.2006, p. 404-412.

Research output: Contribution to journalArticle

Buhl, R, Vinkler, I, Magyar, P, Györi, Z, Rybacki, C, Middle, MV, Escher, A & Engelstätter, R 2006, 'Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma', Pulmonary Pharmacology and Therapeutics, vol. 19, no. 6, pp. 404-412. https://doi.org/10.1016/j.pupt.2005.10.003
Buhl, Roland ; Vinkler, Ilona ; Magyar, P. ; Györi, Zsuzsa ; Rybacki, Cezary ; Middle, Michelle Vivienne ; Escher, Armella ; Engelstätter, Renate. / Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. In: Pulmonary Pharmacology and Therapeutics. 2006 ; Vol. 19, No. 6. pp. 404-412.
@article{5a632c5dbf2a4ed789a5846138389384,
title = "Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma",
abstract = "Background: Inhaled corticosteroids are the mainstay of therapy in asthma, but local and systemic side effects and adherence remain a concern. Ciclesonide is an inhaled corticosteroid with on-site lung activation that provides potent anti-inflammatory activity and has been shown to have a good safety profile, even at high doses. Objective: The aim of this study was to compare the efficacy and safety of once-daily ciclesonide versus twice-daily fluticasone propionate at comparable daily doses in patients with asthma. Methods: In this multicenter, randomized, double-blind, double-dummy, parallel group study, 529 patients were randomized to ciclesonide 160 μg once daily or fluticasone propionate 88 μg twice daily for 12 weeks. The primary endpoint was change in lung function. Results: Both ciclesonide and fluticasone propionate significantly improved forced expiratory volume in 1 s, forced vital capacity, and morning peak expiratory flow compared with baseline (p <0.0001 for all variables). Both medications reduced asthma symptoms and rescue medication use within the first 24 h. At the tested dose, both medications were equally safe and well tolerated. Conclusion: Ciclesonide 160 μg once daily was as effective as fluticasone propionate 88 μg twice daily in improving lung function and asthma symptoms, and in reducing rescue medication use in patients with asthma.",
keywords = "Asthma, Ciclesonide, Fluticasone propionate, Inhaled corticosteroid, Oral candidiasis, Pulmonary function",
author = "Roland Buhl and Ilona Vinkler and P. Magyar and Zsuzsa Gy{\"o}ri and Cezary Rybacki and Middle, {Michelle Vivienne} and Armella Escher and Renate Engelst{\"a}tter",
year = "2006",
month = "12",
doi = "10.1016/j.pupt.2005.10.003",
language = "English",
volume = "19",
pages = "404--412",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma

AU - Buhl, Roland

AU - Vinkler, Ilona

AU - Magyar, P.

AU - Györi, Zsuzsa

AU - Rybacki, Cezary

AU - Middle, Michelle Vivienne

AU - Escher, Armella

AU - Engelstätter, Renate

PY - 2006/12

Y1 - 2006/12

N2 - Background: Inhaled corticosteroids are the mainstay of therapy in asthma, but local and systemic side effects and adherence remain a concern. Ciclesonide is an inhaled corticosteroid with on-site lung activation that provides potent anti-inflammatory activity and has been shown to have a good safety profile, even at high doses. Objective: The aim of this study was to compare the efficacy and safety of once-daily ciclesonide versus twice-daily fluticasone propionate at comparable daily doses in patients with asthma. Methods: In this multicenter, randomized, double-blind, double-dummy, parallel group study, 529 patients were randomized to ciclesonide 160 μg once daily or fluticasone propionate 88 μg twice daily for 12 weeks. The primary endpoint was change in lung function. Results: Both ciclesonide and fluticasone propionate significantly improved forced expiratory volume in 1 s, forced vital capacity, and morning peak expiratory flow compared with baseline (p <0.0001 for all variables). Both medications reduced asthma symptoms and rescue medication use within the first 24 h. At the tested dose, both medications were equally safe and well tolerated. Conclusion: Ciclesonide 160 μg once daily was as effective as fluticasone propionate 88 μg twice daily in improving lung function and asthma symptoms, and in reducing rescue medication use in patients with asthma.

AB - Background: Inhaled corticosteroids are the mainstay of therapy in asthma, but local and systemic side effects and adherence remain a concern. Ciclesonide is an inhaled corticosteroid with on-site lung activation that provides potent anti-inflammatory activity and has been shown to have a good safety profile, even at high doses. Objective: The aim of this study was to compare the efficacy and safety of once-daily ciclesonide versus twice-daily fluticasone propionate at comparable daily doses in patients with asthma. Methods: In this multicenter, randomized, double-blind, double-dummy, parallel group study, 529 patients were randomized to ciclesonide 160 μg once daily or fluticasone propionate 88 μg twice daily for 12 weeks. The primary endpoint was change in lung function. Results: Both ciclesonide and fluticasone propionate significantly improved forced expiratory volume in 1 s, forced vital capacity, and morning peak expiratory flow compared with baseline (p <0.0001 for all variables). Both medications reduced asthma symptoms and rescue medication use within the first 24 h. At the tested dose, both medications were equally safe and well tolerated. Conclusion: Ciclesonide 160 μg once daily was as effective as fluticasone propionate 88 μg twice daily in improving lung function and asthma symptoms, and in reducing rescue medication use in patients with asthma.

KW - Asthma

KW - Ciclesonide

KW - Fluticasone propionate

KW - Inhaled corticosteroid

KW - Oral candidiasis

KW - Pulmonary function

UR - http://www.scopus.com/inward/record.url?scp=33747156391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747156391&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2005.10.003

DO - 10.1016/j.pupt.2005.10.003

M3 - Article

C2 - 16310388

AN - SCOPUS:33747156391

VL - 19

SP - 404

EP - 412

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 6

ER -